Quinoline analogues and nanocarrier systems: A dual approach to anti-tubercular therapy

Mycobacterium tuberculosis (MTB) is the agent that causes tuberculosis (TB), the most lethal infectious illness that affects around one-third of the global population and has resulted in 1.5 million fatalities in recent years. As of right now, sensitive MTB strain-caused tuberculosis can be successfully treated with short-term tuberculosis therapy regimens. However, an increasing issue in many nations is tuberculosis brought on by multidrugresistant (MDR) and extensively drug-resistant (XDR) MTB strains. In recent years, TB has remained major global public health issue. The screening of novel bioactive compounds with new targets and alternative mechanisms of action is urgently needed. The WHO is working to eliminate tuberculosis globally and has set the goal of reducing TB case by 90 % and incidence 80 % by 2035 as part of the sustainable development Goals. Quinoline-based heterocyclic compounds have become quite important in medical chemistry. Due to the exceptional outcomes of their derivatives, quinoline hydrazone scaffold is crucial in the creation of anti-tubercular drugs. The synthetic flexibility of quinoline, which enables the creation of a vast variety of structurally diverse hydrazone derivatives and their metal complexes, has further aided this wide range of biological and biochemical activities.